Surgical risk-reduction in carriers of BRCA mutations: Where do we go from here?

Gynecologic Oncology

Volumn 93, Issue 2, 2004, Pages 277-279

  Kauff, Noah D ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; EDITORIAL; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GYNECOLOGIC CANCER; GYNECOLOGIC SURGERY; HARM REDUCTION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; LAPAROSCOPY; MORBIDITY; OVARY CANCER; PATIENT CARE; PERITONEUM CANCER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SURGICAL RISK; UTERINE TUBE CARCINOMA; UTERUS CARCINOMA; VAGINAL HYSTERECTOMY;

FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; PERITONEAL NEOPLASMS;

EID: 1942445041     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.016     Document Type: Editorial

References (21)

1. Rosen B., Kwon J., Fung Kee Fung M.et al. Systematic review of management options for women with a hereditary predisposition to ovarian cancer. Gynecol Oncol. 93:2004;277-279.
2. Kauff N.D., Satagopan J.M., Robson M.E.et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 346:2002;1609-1615.
3. Rebbeck T.R., Lynch H.T., Neuhausen S.L.et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 346:2002;1616-1622.
4. Rutter J.L., Wacholder S., Chetrit A.et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst. 95:2003;1072-1078.
5. Struewing J.P., Hartge P., Wacholder S.et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336:1997;1401-1408.
6. Ford D., Easton D.F., Stratton M.et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 62:1998;676-689.
7. Satagopan J.M., Boyd J., Kauff N.D.et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 8:2002;3776-3781.
8. King M.C., Marks J.H., Mandell J.B. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 302:2003;643-646.
9. Colgan T.J., Murphy J., Cole D.E., Narod S., Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 25:2001;1283-1289.
10. Lu K.H., Garber J.E., Cramer D.W.et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 18:2000;2728-2732.
11. Karlan B.Y. Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecol Oncol. 92:2004;519-520.
12. Piver M.S., Jishi M.F., Tsukada Y., Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 71:1993;2751-2755.
13. Lavie O., Hornreich G., Ben-Arie A.et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol. 92:2004;521-524.
14. Levine D.A., Lin O., Barakat R.R.et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol. 80:2001;395-398.
15. Rose P.G. Endometrial carcinoma. N Engl J Med. 335:1996;640-649.
16. Jemal A., Tiwari R.C., Murray T.et al. Cancer statistics, 2004. CA Cancer J Clin. 54:2004;8-29.
17. Havrilesky L.J., Peterson B.L., Dryden D.K.et al. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstet Gynecol. 102:2003;243-451.
18. Robson M., Hensley M., Barakat R.et al. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol. 89:2003;281-287.
19. Rebbeck T.R., Levin A.M., Eisen A.et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 91:1999;1475-1479.
20. Armstrong K., Schwartz J.S., Randall T., Rubin S.C., Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with mutations: a decision analysis. J Clin Oncol. 22:2004;1045-1054.
21. Garber J.E., Hartman A.R. Prophylactic oophorectomy and hormone replacement therapy: protection at what price? J Clin Oncol. 22:2004;978-980.